Key Highlights
- KOMZIFTI net product Revenue was USD 13.9 million in the third quarter ended September 30, 2026, versus none a year earlier, and USD 28.8 million for the first nine months after launch in November 2025.
- Collaboration revenue from the Kyowa Kirin agreement fell to USD 8.9 million from USD 20.8 million, leaving calculated total revenue of USD 22.8 million as product sales filled most of the gap.
- Net loss narrowed to USD 70.2 million, or USD 0.78 per share, from USD 74.1 million, or USD 0.85 per share, as Research and Development eased to USD 66.9 million.
- Cash, cash equivalents and short-term investments were USD 492.1 million at September 30, 2026, which the filing said funds the operating plan into 2028, before a new USD 50.0 million loan.
KOMZIFTI Launch Adds Product Revenue as Partner Income Declines
Kura Oncology (NASDAQ:KURA) filed its Quarterly Report on November 10, 2026 and held its call on November 11, 2026. KOMZIFTI, a once-daily oral menin inhibitor for relapsed or refractory NPM1-mutated acute myeloid leukemia, generated USD 13.9 million, which management said was up 53% from the prior quarter, with new patient starts up 30%. Collaboration revenue dropped USD 11.9 million (calculated) to USD 8.9 million, so calculated total revenue of USD 22.8 million was about 9% above the USD 20.8 million of a year earlier. The filing says Parity coverage covers more than 95% of insured lives in the United States.
A USD 70.2 Million Loss Despite Flat Spending
Research and development was USD 66.9 million against USD 67.9 million, with ziftomenib costs of USD 37.2 million, and selling, general and administrative expense fell to USD 30.2 million from USD 32.8 million. Loss from operations was USD 74.7 million versus USD 80.0 million. Nine-month net loss rose to USD 211.9 million from USD 197.7 million. In September 2026, the company formed Caspian Therapeutics to develop a menin inhibitor for diabetes, which raised USD 50.0 million in a Series A round, with Kura investing USD 4.3 million for about 49.2%. A deconsolidation gain of about USD 30.6 million was offset by an equal Equity method loss.
New Loan, Royalty Terms and Guidance on the Call
On November 9, 2026 the company borrowed USD 50.0 million under a new Loan agreement, used part to repay an earlier facility, and may draw up to USD 225.0 million more in tranches. A royalty participation on U.S. sales of ziftomenib begins October 1, 2028, capped at 20.0% of principal funded. Management said on the call that it expects 2026 collaboration revenue of USD 40 million to USD 45 million and USD 90 million to USD 110 million in each of 2027 and 2028, noting this is non-cash recognition, and that cash plus about USD 180 million of anticipated partner payments should support operations beyond the first frontline Phase 3 readout expected in 2028. Jennifer Fulk became Chief Financial Officer on September 8, 2026.
Where Things Stand
Not yet, though the gap is narrowing slowly. Kura Oncology (NASDAQ:KURA) lost USD 70.2 million in the quarter even as KOMZIFTI sales reached USD 13.9 million, because research spending of USD 66.9 million still dwarfs product income. The Balance Sheet of USD 492.1 million, plus the new loan, covers the plan into 2028 on management's view, and partner collaboration income is guided to rebound in 2027 on non-cash accounting. Next markers are data on ziftomenib combinations at the upcoming American Society of Hematology meeting, further loan draws and the Phase 3 readout timeline.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...